Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Blood (2024) 144 (Supplement 1): 5.

https://doi.org/10.1182/blood-2024-199718

Published: 2024

Journal Articles

Real-Life Use of Asciminib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Results of the Turkish Managed Access Program

Blood (2024) 144 (Supplement 1): 6588.

https://doi.org/10.1182/blood-2024-202019

Published: 2024

Journal Articles

Real-Life Outcomes of Bosutinib in Patients with Chronic Myeloid Leukemia: A Multicenter Nationwide Study from Turkey

Serkan Guven, Deniz Özmen, Yunus Çatma, Tuba Güllü Koca, Onur Kırkızlar, Ömer Şeker, Sercan Ünal, Seçil Salim, Betül Kübra Tüzün, Aslı Yüksel Öztürkmen, Nergiz Erkut, Esra Kiriktir, Nesibe Taşer Kanat, Püsem Patır, Abdülkadir Karışmaz, Seval Akpınar, Emel Gürkan, Nurcan Özçelik Kürkçü, Öznur Aydın, Gülsüm Çağlıyan, Ayfer Gedük, Süleyman Arslan, Zehra Narlı Özdemir, Rafiye Çiftçiler, Ayşe Uysal, Merve Aydoğan, Yıldız İpek, Merve Ecem Erdoğan Yön, Zeynep Tuğba Karabulut, Emel Bostan, Sinan Mersin, Tarık Onur Tiryaki, Vildan Gürsoy, İrfan Yavaşoğlu, Ali Doğan, Güchan Alanoğlu, Mehmet Baysal, Eren Arslan Davulcu, Ayşe Kaya, İbrahim Ethem Pınar, Abdülkerim Yıldız, Gülşah Akyol, İnci Alacacıoğlu, Mutlu Arat, Mesut Ayer, Meltem Aylı, İlhami Berber, Ahmet Muzaffer Demir, İbrahim Haznedaroğlu, Fehmi Hindilerden, Erdal Kurtoğlu, Meliha Nalçacı, Fahir Özkalemkaş, Vildan Özkocaman, Güray Saydam, Mehmet Sönmez, Selami Koçak Toprak, Tülin Tuğlular, Burhan Turgut, Mehmet Turgut, Ahmet Emre Eskazan

Blood (2024) 144 (Supplement 1): 6585.

https://doi.org/10.1182/blood-2024-193433

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Blood (2024) 144 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2024-200323

Published: 2024

Journal Articles

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Waleed Ghanima, Howard A. Liebman, Yu Hu, Yoshitaka Miyakawa, Nichola Cooper, Güray Saydam, Marie Luise Hütter-Krönke, Sylvain Audia, Mengjie Yao, Ahmed Daak, Imene Gouia, Matias Cordoba, David J Kuter

Blood (2024) 144 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2024-200279

Published: 2024

Journal Articles

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4442.

https://doi.org/10.1182/blood-2023-186800

Published: 2023

Journal Articles

A Case Series of CML Patients Who Were Presented with Isolated Thrombocytosis

Volkan Karakuş, Vedat Aslan, Güleycan Parça, Omur Gökmen Sevindik, Fatma Keklik Karadag, Erdal Kurtoğlu, Güray Saydam

Blood (2022) 140 (Supplement 1): 12236–12237.

https://doi.org/10.1182/blood-2022-167197

Published: 2022

Journal Articles

An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy

Blood (2021) 138 (Supplement 1): 4730.

https://doi.org/10.1182/blood-2021-150175

Published: 2021

Journal Articles

Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study

Francesco Passamonti, MD, Francesca Palandri, MD PhD, Guray Saydam, MD, Miklos Egyed, MD PhD, Jeannie Callum, MD FRCPC, Timothy Devos, MD, Serdar Sivgin, MD, Paola Guglielmelli, MD, Alessandro M. Vannucchi, MD, Evren Zor, MD, Geralyn Gilotti, MSc, Yifan Zhang, PhD, Martin Griesshammer, MD PhD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139281

Published: 2020

Journal Articles

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Blood (2019) 134 (Supplement_1): 4805.

https://doi.org/10.1182/blood-2019-128743

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Blood (2019) 134 (Supplement_1): 5476.

https://doi.org/10.1182/blood-2019-126402

Published: 2019

Journal Articles

Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study

Francesco Passamonti, MD, Francesca Palandri, PhD MD, Guray Saydam, MD, Giulia Benevolo, MD, Miklos Egyed, MD PhD, Jeannie Callum, MD, Timothy Devos, Serdar Sivgin, MD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD, Caroline Bensasson, Albert Kandra, Juliane Morando, MD, Martin Griesshammer, MD PhD

Blood (2018) 132 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2018-99-115350

Published: 2018

Journal Articles

Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)

Francesco Passamonti, MD, Martin Griesshammer, MD, Michele Cavo, MD, Miklos Egyed, MDPhD Prof., Giulia Benevolo, MD, Timothy Devos, MDPhD, Jeannie Callum, MD, Alessandro M. Vannucchi, MD, Serdar Sivgin, MD, Caroline Bensasson, PhD, Mahmudul Khan, PhD, Nadjat Mounedji, MD, Guray Saydam, MD Prof

Blood (2015) 126 (23): 2807.

https://doi.org/10.1182/blood.V126.23.2807.2807

Published: 2015

Journal Articles

Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update

Guray Saydam, MD Prof, Ibrahim Celalettin Haznedaroglu, MD, Leylagul Kaynar, MD, Akif S. Yavuz, MD Prof, Ridvan Ali, Prof MD, Birol Guvenc, MD Prof, Olga M. Akay, MD, Zafer Baslar, Professor Doctor, Ugur Ozbek, MD PhD, Mehmet Sonmez, MD, Demet Aydin, MD, Mustafa Pehlivan, MD Assoc Prof, Bulent Undar, MD Prof, Simten Dagdas, MD Assoc Prof, Orhan M. Ayyildiz, MD Prof, Diyar Z. Akkaynak, MD, Ilkiz M. Dag, MD, Osman Ilhan, MD

Blood (2014) 124 (21): 5532.

https://doi.org/10.1182/blood.V124.21.5532.5532

Published: 2014

Journal Articles

The Clinical Characteristics and Therapeutic Outcomes of Elderly Patients with Chronic Lymphocytic Leukemia: A Retrospective Multicenter Study

Blood (2014) 124 (21): 5644.

https://doi.org/10.1182/blood.V124.21.5644.5644

Published: 2014

Journal Articles

Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia

Guray Saydam, MD, Prof, Ibrahim C. Haznedaroglu, MD, Prof, Leylagul Kaynar, MD, Prof, Akif S. Yavuz, MD, Prof, Ridvan Ali, MD, Prof, Birol Guvenc, MD, Prof, Olga M. Akay, MD, Zafer Baslar, Professor Doctor, Ugur Ozbek, MD, Prof, Mehmet Sonmez, M.D., Demet Aydin, MD, Mustafa Pehlivan, MD, Assoc Prof, Bulent Undar, MD, Prof, Simten Dagdas, MD, Assoc Prof, Orhan M. Ayyildiz, MD, Prof, Diyar Z. Akkaynak, MD, Ilkiz M. Dag, MD, Osman Ilhan, MD, Prof

Blood (2013) 122 (21): 2742.

https://doi.org/10.1182/blood.V122.21.2742.2742

Published: 2013

Journal Articles

Polyethylene Glycol - Polyethylenimine Nanoparticle-Mediated Transfection of Mir-150 Into the Leukemia Cells and Determination of the Expression Pattern Changes in Apoptosis and Cell Cycle Genes

Tugce Balci, Cigir Biray Avci, Ipek Ozcan, Sunde Yilmaz Susluer, Cagla Kayabasi, Guray Saydam, MD, Cumhur Gunduz

Blood (2012) 120 (21): 4679.

https://doi.org/10.1182/blood.V120.21.4679.4679

Published: 2012

Journal Articles

The Potential Role of STAT's in Anti-Leukemic Therapy with Different Drugs

Hatice Demet Kiper, Burcin Tezcanli Kaymaz, Ozlem Purclutepe, Ceyda Tunakan Dalgic, Nur Selvi, Aysegul Dalmizrak, Cigir Biray Avci, Buket Kosova, Fahri Sahin, Cagdas Aktan, Guray Saydam, MD

Blood (2012) 120 (21): 5120.

https://doi.org/10.1182/blood.V120.21.5120.5120

Published: 2012

Journal Articles

Autophagic and Apoptotic Effects of Tyrosine Kinase Inhibitors in Myeloid Leukemia: Comparison of Three Generation

Cagla Kayabasi, Cigir Biray Avci, Sunde Yilmaz Susluer, Tugce Balci, Yusuf Baran, Guray Saydam, MD, Cumhur Gunduz

Blood (2012) 120 (21): 4915.

https://doi.org/10.1182/blood.V120.21.4915.4915

Published: 2012

Journal Articles

Radioisotope Synovectomy for Treating Chronic Synovitis in Inhibitor Patients with Hemophilia.

Kaan Kavakli, MD, Semih Aydogdu, MD, Yusuf Duman, MD, Memduh Taner, PhD, Guray Saydam, MD, Kazim Capaci, MD, Aysenur Oktay, MD, Can Balkan, MD, Deniz Yilmaz, MD

Blood (2006) 108 (11): 4005.

https://doi.org/10.1182/blood.V108.11.4005.4005

Published: 2006

NARROW

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Real-Life Use of Asciminib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Results of the Turkish Managed Access Program

Real-Life Outcomes of Bosutinib in Patients with Chronic Myeloid Leukemia: A Multicenter Nationwide Study from Turkey

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

A Case Series of CML Patients Who Were Presented with Isolated Thrombocytosis

An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy

Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study

Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)

Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update

The Clinical Characteristics and Therapeutic Outcomes of Elderly Patients with Chronic Lymphocytic Leukemia: A Retrospective Multicenter Study

Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia

Polyethylene Glycol - Polyethylenimine Nanoparticle-Mediated Transfection of Mir-150 Into the Leukemia Cells and Determination of the Expression Pattern Changes in Apoptosis and Cell Cycle Genes

The Potential Role of STAT's in Anti-Leukemic Therapy with Different Drugs

Autophagic and Apoptotic Effects of Tyrosine Kinase Inhibitors in Myeloid Leukemia: Comparison of Three Generation

Radioisotope Synovectomy for Treating Chronic Synovitis in Inhibitor Patients with Hemophilia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only